You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Claims for Patent: 10,195,233


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,195,233
Title:Postpartum cells derived from placental tissue, and methods of making and using the same
Abstract: Cells derived from postpartum placenta and methods for their isolation are provided by the invention. The invention further provides cultures and compositions of the placenta-derived cells. The placenta-derived cells of the invention have a plethora of uses, including but not limited to research, diagnostic, and therapeutic applications.
Inventor(s): Kihm; Anthony J. (Princeton, NJ), Harris; Ian Ross (Radnor, PA), Mistry; Sanjay (Downington, PA), Harmon; Alexander M. (Clinton, NJ), Messina; Darin J. (Downington, PA), Seyda; Agnieszka (Edison, NJ), Yi; Chin-Feng (Hillsborough, NJ), Gosiewska; Anna (Skillman, NJ)
Assignee: DePuy Synthes Products, Inc. (Raynham, MA)
Application Number:15/443,718
Patent Claims:1. A method of isolating a placenta-derived cell from a human postpartum placenta comprising dissociating said cell from said placenta with a matrix metalloprotease, a neutral protease, and a mucolytic enzyme that digests hyaluronic acid, wherein the isolated placenta-derived cell is obtained from human postpartum placenta substantially free of blood, and wherein the placenta-derived cell has the following characteristics: a) self-renews and expands in culture; b) is multipotent; c) produces CD10, CD13, CD44, CD73, CD90, PDGFr-alpha, PD-L2 and HLA-A,B,C; d) does not produce CD31, CD34, CD45, CD80, CD86, CD117, CD141, CD178, B7-H2, HLA-G or HLA-DR-DP,DQ; and e) expresses, relative to a human fibroblast, mesenchymal stem cell, or iliac crest bone marrow cell, increased levels of oxidized low density lipoprotein receptor 1 and renin.

2. The method of claim 1, wherein said matrix metalloprotease comprises collagenase.

3. The method of claim 1, wherein said neutral protease comprises dispase.

4. The method of claim 1, wherein said mucolytic enzyme comprises hyaluronidase.

5. The method of claim 1, further comprising mechanically dissociating said placenta prior to said dissociating step.

6. The method of claim 1, further comprising growing said cell in culture medium.

7. The method of claim 6, wherein said culture medium comprises RPMI1640, Ham's F10 medium, Ham's F12 medium, Mesenchymal Stem Cell Growth Medium, Iscove's modified Dulbecco's medium, Dulbecco's modified Eagle's Medium (DMEM), CELL-GRO FREE, DMEM/F12, advanced DMEM, DMEM/MCDB201, or Eagle's basal medium.

8. The method of claim 6, wherein said medium comprises about 2% to about 15% (v/v) serum.

9. The method of claim 6, wherein said medium comprises beta-mercaptoethanol.

10. The method of claim 6, wherein said culture medium comprises at least one antibiotic agent.

11. The method of claim 6, wherein said culture medium comprises glucose.

12. The method of claim 6, wherein said culture medium comprises L-valine.

13. The method of claim 6, wherein said culture medium comprises DMEM-low glucose, beta-mercaptoethanol, serum, and an antibiotic agent.

14. The method of claim 1, further comprising cryopreserving said placenta-derived cell.

15. The method of claim 1, further comprising banking said placenta-derived cell.

16. The method of claim 1, further comprising expanding said isolated cells on an uncoated surface.

17. The method of claim 1, further comprising expanding said isolated cells on a coated surface.

18. The method of claim 17, wherein said surface is coated with at least one of gelatin, collagen, fibronectin, laminin, ornithine, vitronectin, or extracellular membrane protein.

19. The method of claim 6, wherein the culture medium is protein-free culture medium.

20. The method of claim 6, wherein the culture medium is serum-free culture medium.

21. The method of claim 1, wherein the placenta-derived cell lacks production of GRO-alpha and oxidized low density lipoprotein receptor, as detected by flow cytometry.

22. The method of claim 1, wherein the placenta-derived cell further has the following characteristics: (a) secretion of monocyte chemotactic protein 1 (MCP-1), interleukin-6 (IL-6), interleukin 8 (IL8), hepatocyte growth factor (HGF), keratinocyte growth factor (KGF), heparin-binding epidermal growth factor (HB-EGF), brain-derived neurotrophic factor (BDNF), tissue inhibitor of matrix metalloproteinase 1 (TIMP1), thrombopoietin (TPO), macrophage inflammatory protein 1alpha(MIP1a), Rantes (regulated on activation, normal T cell expressed and secreted), thymus and activation-regulated chemokine (TARC), and Eotaxin; and (b) lack of secretion of fibroblast growth factor (FGF), vascular endothelial growth factor (VEGF), angiopoietin 2 (ANG2), platelet derived growth factor (PDGF-bb), transforming growth factor beta2 (TGFbeta2), macrophage inflammatory protein 1beta (MIP1b), I309, and macrophage-derived chemokine (MDC), as detected by ELISA.

23. The method of claim 1, wherein the placenta-derived cell is of a neonatal origin.

24. The method of claim 1, wherein said placenta-derived cell is of a maternal origin.

25. The method of claim 1, wherein the placenta-derived cell has the ability to differentiate into a mesodermal, ectodermal, or endodermal phenotype.

26. The method of claim 1, wherein the placenta-derived cell can undergo at least 40 population doublings in culture.

27. The method claim 1, further comprising genetically engineering the isolated cell to produce a protein of interest.

28. The method of claim 1, wherein the isolated placenta-derived cell is identified by ATCC Accession No. PTA-6074.

29. The method of claim 1, wherein the isolated placenta-derived cell is identified by ATCC Accession No. PTA-6075.

30. The method of claim 1, wherein the isolated placenta-derived cell is identified by ATCC Accession No. PTA-6079.

31. The method of claim 1, wherein the isolated placenta-derived cell expresses granulocyte chemotactic protein-2 (GCP-2).

Details for Patent 10,195,233

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Bausch & Lomb Incorporated VITRASE hyaluronidase Injection 021640 05/05/2004 ⤷  Try a Trial 2023-06-27
Bausch & Lomb Incorporated VITRASE hyaluronidase Injection 021640 12/02/2004 ⤷  Try a Trial 2023-06-27
Amphastar Pharmaceuticals, Inc. AMPHADASE hyaluronidase Injection 021665 10/26/2004 ⤷  Try a Trial 2023-06-27
Akorn, Inc. HYDASE hyaluronidase Injection 021716 10/25/2005 ⤷  Try a Trial 2023-06-27
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.